Latest California Healthline Stories
Readers Issue Rx for Clogged ERs and Outrageous Out-of-Pocket Costs
California Healthline gives readers a chance to comment on a recent batch of stories.
KFF Health News' 'What the Health?': Waiting for SCOTUS
June is when the Supreme Court typically issues rulings in the major cases it hears during that year’s term. This year, those interested in health policy are awaiting decisions in two abortion-related cases and one that could reshuffle the way health policies (and all other federal policies) are made. In this special episode, KFF’s Laurie Sobel, associate director for women’s health policy, joins Julie Rovner for a review of the cases and a preview of how the court might rule.
An Obscure Drug Discount Program Stifles Use of Federal Lifeline by Rural Hospitals
A disconnect between two federal programs meant to help keep hospitals afloat discourages struggling rural facilities from accepting the aid.
High Price of Popular Diabetes Drugs Deprives Low-Income People of Effective Treatment
The makers of Ozempic and Mounjaro charge list prices of around $1,000 a month for the diabetes and obesity drugs, and insurers are reluctant to pick up the tab. Often, low-income patients have to resort to less effective treatments.
Personas de bajos ingresos no pueden recibir terapias efectivas contra la diabetes por el alto costo
La escasez de suministros y las barreras que ponen las aseguradoras para obtener esta poderosa clase de medicamentos, llamados agonistas de GLP-1, han dejado a muchas personas que viven con diabetes y obesidad sin los medicamentos que necesitan para mantenerse saludables.
Amgen Plows Ahead With Costly, Highly Toxic Cancer Dosing Despite FDA Challenge
The FDA told Amgen to test whether a quarter-dose of its lung cancer drug worked as well as the amount recommended on the product label. It did and with fewer side effects. But Amgen is sticking to the higher dose — which earns it an additional $180,000 a year per patient.
What’s Keeping the US From Allowing Better Sunscreens?
A decade after Congress told the FDA to expedite the approval of more effective sunscreens, the federal government still has not approved sunscreen ingredients that are safely being used around the world. Meanwhile, skin cancer is the nation’s most common cancer.
KFF Health News' 'What the Health?': Abortion Access Changing Again in Florida and Arizona
A six-week abortion ban took effect in Florida this week, dramatically restricting access to the procedure not just in the nation’s third-most-populous state but across the South. Patients from states with even more restrictive bans had been flooding in since the overturn of Roe v. Wade in 2022. Meanwhile, the CEO of the health behemoth UnitedHealth Group appeared before committees in both the House and Senate, where lawmakers grilled him about the February cyberattack on subsidiary Change Healthcare and how its ramifications are being felt months later. Alice Miranda Ollstein of Politico, Sarah Karlin-Smith of the Pink Sheet, and Rachana Pradhan of KFF Health News join KFF Health News’ Julie Rovner to discuss these stories and more. Plus, for “extra credit,” the panelists suggest health policy stories they read this week they think you should read, too.
Readers Speak Up About Women’s Health Issues, From Reproductive Care to Drinking
California Healthline gives readers a chance to comment on a recent batch of stories.
Ten Doctors on FDA Panel Reviewing Abbott Heart Device Had Financial Ties With Company
Most of the doctors the FDA tapped to advise it on an Abbott medical device had financial ties to the company. The FDA didn’t disclose the payments.